Serial No.: 09/973,994

Response to Office Communication

AMENDMENT TO THE CLAIMS

- 1. (Withdrawn) A relational database comprising the data of Table I.
- 2. (Currently Amended) A method of staging conifer embryos comprising:
 - a) detecting the expression in a conifer embryo of at least one RNA transcript wherein the RNA transcript is capable of hybridizing to at least one cDNA sequence of SEQ ID NO: 79 or 131 under high stringency conditions; and
 - b) correlating the expression of said transcript to one or more embryonic stages.
- 3. (Previously Presented) The method of claim 2 wherein at least two RNA transcripts are detected or determined and correlated to one or more embryonic stages.
- 4. (Previously Presented) The method of claim 2 wherein expression of the at least one RNA transcript is analyzed by hybridization with at least one probe of sequence SEQ ID NO: 79 or 131.
- 5. (Cancelled) The method of claim 2 wherein expression of the at least one RNA transcript is analyzed by hybridization with a variant of at least one probe of Table I.
- 6. (Cancelled) The method of claim 5 wherein said variant hybridizes to at least one probe of Table I under conditions of high stringency.
- 7. (Withdrawn) The method of claim 5 wherein said variant hybridizes to at least one probe of Table I under conditions of moderate stringency.
- 8. (Currently Amended) The method of claim 2 wherein expression of at least one RNA transcript is detected or determined by one or more of at least one member of the group consisting of PCR, Northern Analysis, or and in situ hybridization.

Serial No.: 09/973,994

Response to Office Communication

9. (Previously Presented) The method of claim 2 wherein expression of said at least two

RNA transcripts are detected by a DNA array.

10. (Withdrawn) A database comprising a multiplicity of nucleotide sequences shown in

any one of Table I, including variants thereof, wherein said variants hybridize under conditions

of high stringency to either strand of a denatured, double-stranded DNA comprising any of SEQ

ID NOS: 1-327.

11. (Withdrawn) The database of claim 10 wherein said variants hybridize under conditions

of moderate stringency.

12. (Withdrawn) A DNA array comprising a multiplicity of nucleotide sequences shown in

Table I, including variants thereof, wherein said variants hybridize under conditions of high

stringency to either strand of a denatured, double-stranded DNA comprising any of SEQ ID

NOS: 1-327.

13. (Withdrawn) The DNA array of claim 12 wherein said variants hybridize under

conditions of moderate stringency.

14. (Withdrawn) A method for staging plant embryos comprising:

a) selecting total RNA from a multiplicity of embryos of known developmental age;

b) correlating the embryonic expression pattern to the developmental age to develop

a relational database;

c) determining levels of expression from embryos of unknown developmental age

by hybridization to a DNA array comprising a multiplicity of the nucleotide

sequences shown in any one of SEQ ID NOS: 1-327;

d) correlating the expression pattern from step 3 to the relational database to

determine developmental stage for the unknown embryo.

1613030_1.DOC

3

Serial No.: 09/973,994

Response to Office Communication

15. (Withdrawn) The method of claim 14 wherein the embryos of step 1) are zygotic embryos.

- 16. (Withdrawn) The method of claim 14 further comprising the step of altering the embryonic growth conditions to approximate the expression pattern of zygotic embryos.
- 17. (Withdrawn) An isolated nucleic acid variant of the nucleotide sequence shown in any one of SEQ ID NOS: 1-334, wherein said variant hybridizes under conditions of moderate stringency to either strand of a denatured, double-stranded DNA comprising any of SEQ 1D NOS: 1-334.
- 18. (Withdrawn) An isolated polypeptide encoded by a nucleic acid molecule of claim 17.
- 19. (Withdrawn) An isolated nucleic acid encoding the polypeptide of claim 18.
- 20. (Withdrawn) Antibodies that specifically bind to the peptide of claim 18.
- 21. (Withdrawn) The antibodies of claim 20, wherein said antibodies are monoclonal.
- 22. (Withdrawn) A recombinant vector that directs the expression of a nucleic acid of claim
- 17.
- 23. (Withdrawn) A host cell transformed with the vector of claim 22.
- 24. (Withdrawn) The host cell of claim 23, wherein the host is a somatic pine embryo.
- 25. (Withdrawn) A method for staging plant embryos comprising:
 - a) selecting total RNA from at least one embryo of known developmental age;
 - b) determining the level of expression of a multiplicity of genes which hybridize to one or more of SEQ ID NOS: 1-327;

Serial No.: 09/973,994

Response to Office Communication

c) correlating the known developmental ages of the embryos from step 1) with the profile of expression measured in step 2);

- d) applying the correlation of step 3) to a sample of embryo RNA from embryos to be staged; and
- e) determining the embryo stage.
- 26. (Withdrawn) The method of claim 25, wherein the measurement of gene expression is by RT-PCR.
- 27. (Withdrawn) The method of claim 25, wherein the measurement of gene expression is by nucleic acid hybridization.
- 28. (Withdrawn) The method of claim 25, wherein the measurement of gene expression is by determining the level of protein expression.
- 29. (Withdrawn) The method of claim 28, wherein protein expression is measured by antibody binding.
- 30. (Withdrawn) A method for selecting advantageous plant clones comprising:
 - Selecting one or more samples of embryonic RNA from multiple clones of plants;
 - b) Determining that at least one sampled clone has an advantageous characteristic;
 - c) Comparing the embryonic levels of expression of genes which hybridize to one or more of SEQ ID NOS: 1-327 in samples from the advantageous clone with expression levels in at least one clone that does not show the advantageous characteristic; and
 - d) Selecting additional clones which show an embryonic gene expression pattern more similar to that of the advantageous clone than to the pattern of at least one clone that does not show the advantageous characteristic.

Serial No.: 09/973,994

Response to Office Communication

31. (Withdrawn) Method of claim 30 where the clones to be sampled or compared are from

about the same developmental age.

32. (Withdrawn) Method of claim 31 where the development age is visually detected.

33. (Withdrawn) The method of claim 30, wherein the measurement of gene expression is

by RT-PCR.

34. (Withdrawn) The method of claim 30, wherein the measurement of gene expression is

by nucleic acid hybridization.

35. (Withdrawn) The method of claim 30, wherein the measurement of gene expression is

by determining the level of protein expression.

36. (Withdrawn) The method of claim 35, wherein protein expression is measured by

antibody binding.

37. (Withdrawn) A method of determining embryo fitness comprising:

a) creating a relational database with RNA expression values for genes listed in

Table I for embryos of known developmental stages;

b) isolating total RNA from embryos of unknown stage development;

c) measuring expression levels of genes identified in Table I from the solated total

RNA; and

d) correlating the database of step 1) with the pattern of expression determined in

steps 2) and 3) to assess proper embryo development.

38. (Withdrawn) The method of claim 37, wherein the measurement of gene expression is

by RT-PCR.

1613030_1.DOC

6

Serial No.: 09/973,994

Response to Office Communication

39. (Withdrawn) The method of claim 37, wherein the measurement of gene expression is by nucleic acid hybridization.

- 40. (Withdrawn) The method of claim 37, wherein the measurement of gene expression is by determining the level of protein expression.
- 41. (Withdrawn) The method of claim 40, wherein protein expression is measured by antibody binding.
- 42. (Withdrawn) A method for selecting advantageous growth conditions for embryo development comprising:
 - a) determining RNA expression profiles for staged embryos under control culture conditions;
 - b) altering culture conditions;
 - c) determining RNA expression profiles for staged embryos under altered culture conditions; and
 - d) correlating culture change to developmental effect in embryo.
- 43. (Withdrawn) The method of claim 42. wherein conditions are selected which produce RNA expression profiles most closely approximating late-stage embryo profiles.
- 44. (Withdrawn) The method of claim 42, wherein the culture conditions are altered by operatively linking one or more stage-specific embryo promoter(s) to one or more sense or antisense nucleic acid molecules.
- 45. (Withdrawn) The method of claim 42, wherein the culture conditions are altered by operatively linking one more stage-specific embryo promoter(s) selected from SEQ 1D NOS: 328-334 to one or more sense or antisense nucleic acid molecules.

Serial No.: 09/973,994

Response to Office Communication

46. (Withdrawn) The method of claim 42, wherein the change in expression profiles is correlated by a relational database.

47. (Withdrawn) A recombinant nucleic acid molecule encoding a product during embryo development comprising:

- a) a first nucleic acid sequence which is the LP2-3 promoter: and
- a second nucleic acid sequence encoding a product, wherein the first nucleic acid is operatively linked to the second nucleic acid molecule whereby its expression is directed by the promoter sequence.
- 48. (Withdrawn) The recombinant nucleic acid molecule of claim 47 wherein the second nucleic acid sequence encodes for GFP, or a variant of GFP.
- 49. (Withdrawn) The recombinant nucleic acid molecule of claim 48 wherein the second nucleic acid sequence is linked to one or more additional nucleic acid molecules.
- 50. (Withdrawn) The recombinant nucleic acid molecule of claim 49 wherein the additional molecule encodes a protein product normally expressed by a developing embryo at a known stage.
- 51. (Withdrawn) The recombinant nucleic acid molecule of claim 47 wherein the second nucleic acid sequence encodes an embryo-derived molecule.
- 52. (Withdrawn) The recombinant nucleic acid molecule of claim 51 embryo-derived molecule is stage-specific.
- 53. (Withdrawn) A plant cell comprising the recombinant nucleic acid molecule of claim 47.

Serial No.: 09/973,994

Response to Office Communication

54. (Withdrawn) A method for producing a protein product during embryo development comprising:

- a) operatively linking one more stage-specific embryo promoter(s) to one or more nucleic acid molecules that encode a protein product,
- b) delivering construct to developing embryos.
- 55. (Withdrawn) The method of claim 54 wherein the operatively linked nucleic acid molecule is a reporter or indicator gene.
- 56. (Withdrawn) The method of claim 54 wherein the operatively linked nucleic acid molecule is GFP, or a variant of GFP.
- 57. (Withdrawn) The method of claim 54 wherein at least one stage-specific promoter is selected from SEQ ID NOS: 328-334.
- 58. (Withdrawn) A method for staging embryos comprising:
 - a) providing one or more stage-specific embryo promoter(s) operatively linked to one or more nucleic acid molecules that encode a protein product to developing embryos,
 - b) monitoring expression of the protein product as the embryo matures through stage in which promoter functions.
- 59. (Withdrawn) The method of claim 58 wherein the operatively linked nucleic acid molecule is a reporter or indicator gene.
- 60. (Withdrawn) The method of claim 58 wherein the operatively linked nucleic acid molecule is GFP, or a variant of GFP.
- 61. (Withdrawn) The method of claim 58 wherein at least one stage-specific promoter is selected from SEQ ID NOS: 328-334.